» Articles » PMID: 38398883

Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms

Overview
Journal Nutrients
Date 2024 Feb 24
PMID 38398883
Authors
Affiliations
Soon will be listed here.
Abstract

The most common malignant gynecologic diseases are cervical, uterine, ovarian, vaginal, and vulvar cancer. Among them, ovarian cancer causes more deaths than any other cancer of the female reproductive system. A great number of women suffer from endometriosis, uterine fibroids (UFs), adenomyosis, dysmenorrhea, and polycystic ovary syndrome (PCOS), which are widespread benign health problems causing troublesome and painful symptoms and significantly impairing the quality of life of affected women, and they are some of the main causes of infertility. In addition to the available surgical and pharmacological options, the effects of supporting standard treatment with naturally occurring compounds, mainly polyphenols, are being studied. Catechins are responsible for the majority of potential health benefits attributed to green tea consumption. Epigallocatechin gallate (EGCG) is considered a non-toxic, natural compound with potential anticancer properties. Antioxidant action is its most common function, but attention is also drawn to its participation in cell division inhibition, apoptosis stimulation and epigenetic regulation. In this narrative review, we describe the role of EGCG consumption in preventing the development of benign reproductive disorders such as UF, endometriosis, and PCOS, as well as malignant gynecologic conditions. We discuss possible epigenetic mechanisms that may be related to the action of EGCG.

Citing Articles

Role of Epigallocatechin Gallate in Selected Malignant Neoplasms in Women.

Markowska A, Antoszczak M, Markowska J, Huczynski A Nutrients. 2025; 17(2).

PMID: 39861342 PMC: 11767294. DOI: 10.3390/nu17020212.


Exploring Strategies to Prevent and Treat Ovarian Cancer in Terms of Oxidative Stress and Antioxidants.

Long Y, Shi H, Ye J, Qi X Antioxidants (Basel). 2025; 14(1).

PMID: 39857448 PMC: 11762571. DOI: 10.3390/antiox14010114.


Research Advances in Adenomyosis-Related Signaling Pathways and Promising Targets.

Zhang H, Li C, Li W, Xin W, Qin T Biomolecules. 2024; 14(11).

PMID: 39595579 PMC: 11591984. DOI: 10.3390/biom14111402.


Bioinformatics Analysis and Experimental Validation of Epigallocatechin-3-gallate Against Iopromide-induced Injury in HEK-293 Cells Anti-oxidative and Anti-inflammation Pathways.

Tsai Y, Tsai C, Yang J, Juan Y, Shih H, Bau D In Vivo. 2024; 38(6):2617-2628.

PMID: 39477405 PMC: 11535936. DOI: 10.21873/invivo.13738.


Research progress and applications of epigenetic biomarkers in cancer.

Gao J, Shi W, Wang J, Guan C, Dong Q, Sheng J Front Pharmacol. 2024; 15:1308309.

PMID: 38681199 PMC: 11048075. DOI: 10.3389/fphar.2024.1308309.

References
1.
Inoue F, Sone K, Toyohara Y, Takahashi Y, Kukita A, Hara A . Targeting Epigenetic Regulators for Endometrial Cancer Therapy: Its Molecular Biology and Potential Clinical Applications. Int J Mol Sci. 2021; 22(5). PMC: 7956745. DOI: 10.3390/ijms22052305. View

2.
Koukoura O, Spandidos D, Daponte A, Sifakis S . DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review). Mol Med Rep. 2014; 10(1):3-9. PMC: 4068729. DOI: 10.3892/mmr.2014.2221. View

3.
Trudel D, Labbe D, Araya-Farias M, Doyen A, Bazinet L, Duchesne T . A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol. 2013; 131(2):357-61. DOI: 10.1016/j.ygyno.2013.08.019. View

4.
Gonzalez C, Travier N, Lujan-Barroso L, Castellsague X, Bosch F, Roura E . Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study. Int J Cancer. 2010; 129(2):449-59. DOI: 10.1002/ijc.25679. View

5.
Laschke M, Schwender C, Scheuer C, Vollmar B, Menger M . Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum Reprod. 2008; 23(10):2308-18. DOI: 10.1093/humrep/den245. View